Cyclic crf antagonist peptides
CA 2291856 A1 · Owner: Rivier, Jean E. F. · Inventors: Rivier, Jean E. F.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Novel cyclic CRF antagonist peptides are created by shortening the N-terminus of a CRF family peptide by 8 residues and adding an acyl group. CML is present in what would be the 27-position of the native CRF sequence and a cyclizing , bond is created between the side chains of the residues in positions 30 and 33. The side chain of Lys, preferably, in position 33 is linked to the side chain of Glu in position 30 by a lactam bridge. Disclosed CRF antagonists include: (cyclo 30-33)Ac-Asp9, D-Phe12 Nle21,38, CML27,40, Glu30, Lys33r/hCRF(9-41); (cyclo 30-33) Ac-Asp9 D-Phe12, CML18,27, Nle21,38, Glu30, Lys33r-hCRF(9-41); (cyclo 30-33)Ac-Asp9 D-Phe12, Nle21,38, CML27,37, Glu30, …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 26, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 26, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 26, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.